Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01791374
Other study ID # 20110251
Secondary ID 20110251
Status Completed
Phase Phase 1
First received January 4, 2013
Last updated February 26, 2016
Start date November 2012
Est. completion date March 2015

Study information

Verified date February 2016
Source Amgen
Contact n/a
Is FDA regulated No
Health authority Japan: Pharmaceuticals and Medical Devices AgencyJapan: Ministry of Health, Labor and Welfare
Study type Interventional

Clinical Trial Summary

This is an open label phase 1/1b study of Rilotumumab in Japanese subjects with advanced solid tumors or metastatic gastric esphagogastric (GEJ) adenocarcinoma.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date March 2015
Est. primary completion date August 2013
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 100 Years
Eligibility Key Inclusion Criteria:

- Japanese subjects with pathologically confirmed unresectable locally advanced or metastatic carcinoma which is refractory to standard therapies or for which there is no standard therapy (Part 1 only)

- Japanese subjects with pathologically confirmed MET-positive (fulfilling the MET IHC criteria as defined by validated IVD [in vitro diagnostic]) unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma (Part 2 only)

- Eastern Cooperative Oncology Group (ECOG) Performance Status (0 or 1)

- Availability of archival tumor tissue (Part 2 only)

- Evaluable (measurable or non-measurable) disease by RECIST 1.1 criteria

- Able to tolerate infusions and take oral medications (Part 2 only)

Key Exclusion Criteria:

- Previous systemic therapy (including chemotherapy, biologic, immunotherapy, or investigational therapy) for locally advanced or metstatic gastric or GEJ adenocarcinoma (Part 2 only)

- Less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant chemotherapy or chemotherapy to enrollment (Part 2 only)

- Squamos cell history (Part 2 only)

- Known HER2-overexpressing unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma (Part 2 only)

- Resectable disease or suitable for definitive chemoradiation

- Subjects who have persistent gastric outlet obstruction, complete dysphagia or are dependent upon jejunostomy for feeding (Part 2 only)

- Known central nervous system metastases

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Rilotumumab
Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
Rilotumumab
Drug: Rilotumumab Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. Drug: Cisplatin A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Drug: Capecitabine A chemo-therapy prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Locations

Country Name City State
Japan Research Site Kashiwa-shi Chiba
Japan Research Site Kawasaki-shi Kanagawa
Japan Research Site Kitaadachi-gun Saitama
Japan Research Site Matsuyama-shi Ehime
Japan Research Site Nagoya-shi Aichi
Japan Research Site Sapporo-shi Hokkaido
Japan Research Site Suntou-gun Shizuoka

Sponsors (1)

Lead Sponsor Collaborator
Amgen

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part1: Dose-limiting toxicities (DLT) for each dose level of rilotumumab tested DLTs are defined as grade 3 or higher adverse events that are related to rilotumumab during the first cycle of therapy. This does not include specific toxicities (eg nausea and vomiting) that are common in cancer patients unless specific criteria are met. 28 days Yes
Primary Part 2: Dose-limiting toxicities (DLT) for each dose level of rilotumumab in combination with cisplatin and capecitabine (CX) chemotherapy tested DLTs are defined as grade 3 or higher adverse events that are related to rilotumumab or the combination of rilotumumab and CX during the first cycle of therapy. This does not include specific toxicities (eg nausea and vomiting) that are common in cancer patients unless specific criteria are met. 21 days Yes
Secondary Part 1: Incidence of AEs, clinical laboratory abnormalities and anti-rilotumumab antibodies. AEs and laboratory abnormalities are reported by CTCAE (version 3.0) criteria 4 months average Yes
Secondary Part 1: Pharmacokinetics parameters of rilotumumab monotherapy as measured by: Maximum concentration, time to achieve maximum concentration, observed minimum concentration, area under the concentration-time curve, terminal elimination half-life. 4 months average Yes
Secondary Part 1: Evaluate efficacy based on the treatment effects of rilotumumab monotherapy as measured by the following: Objective Response Rate, duration of response, progression-free survival. 4 months average No
Secondary Part 2: Incidence of AEs, clinical laboratory abnormalities and anti-rilotumumab antibodies not defined as DLTs. AEs and laboratory abnormalities are reported by CTCAE (version 3.0) criteria 7 months average Yes
Secondary Part 2: Pharmacokinetics parameters of rilotumumab in combination with cisplatin and capecitabine as measured by: Maximum concentration, observed minimum concentration, area under the concentration-time curve. 7 months average Yes
Secondary Part 2: Evaluate efficacy based on the treatment effects of rilotumumab in combination with cisplatin and capecitabine as measured by the following: Objective Response Rate, duration of response, progression-free survival, overall survival. 7 months average No